Relebactam丨CAS 1174018-99-5

Relebactam is a β-lactamase inhibitor that is primarily used in combination with other antibiotics to treat multidrug-resistant bacterial infections. It is most commonly paired with meropenem, a broad-spectrum antibiotic, to enhance its efficacy against certain Gram-negative bacteria, particularly those producing β-lactamases such as KPC (Klebsiella pneumoniae carbapenemase). Relebactam works by inhibiting the activity of these enzymes, which would otherwise degrade the antibiotic and render it ineffective. The compound is used in the treatment of complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs), and pneumonia caused by resistant pathogens. Additionally, the combination of relebactam with meropenem is used in hospital settings to treat infections that are difficult to manage due to antibiotic resistance, providing a critical therapeutic option in the fight against antibiotic-resistant superbugs.

The primary benefit of relebactam is its ability to restore the effectiveness of antibiotics like meropenem against resistant bacteria, particularly those producing β-lactamase enzymes. By inhibiting these enzymes, relebactam allows the antibiotic to target and kill bacteria that would otherwise be resistant, offering significant therapeutic benefits in treating multidrug-resistant infections. Relebactam's role in combination therapy expands the range of pathogens that can be effectively treated, providing a vital tool in the fight against resistant infections, which have become a growing concern in healthcare. Additionally, the compound's use can help reduce the development of further resistance, as it preserves the effectiveness of existing antibiotics, thereby contributing to more sustainable antibiotic use. Overall, relebactam offers a targeted solution to combat infections caused by resistant Gram-negative bacteria, which are often associated with high morbidity and mortality rates.